ArticleJournal of gastrointestinal oncology2026
Clinical efficacy and safety of apatinib plus S-1 combined with oxaliplatin (SOX) in postoperative stage III gastric cancer patients with high VEGFR-2 expression.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The S-1 combined with oxaliplatin (SOX) regimen is the standard adjuvant chemotherapy regimen for stage III gastric cancer (GC) in China, yet 5-year survival remains only 30-40%, partly due to marked tumor heterogeneity. Apatinib, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, has shown significant efficacy in unresectable or metastatic GC and the neoadjuvant treatment of locally advanced GC, with response positively correlated with VEGFR-2 expression. However, SOX + apatinib has not been evaluated as an adjuvant treatment regimen in postoperative stage III GC patients with high VEGFR-2 expression. Therefore, this study aimed to evaluate the efficacy and safety of SOX + apatinib in postoperative stage III GC patients with high VEGFR-2 messenger RNA (mRNA)expression. Methods: In this retrospective single-center study, data of 112 postoperative stage III GC patients with high VEGFR-2 mRNA expression treated at The Affiliated Hospital of Guizhou Medical University between January 2015 and June 2021 were analyzed. Patients received six 21-day cycles of adjuvant SOX alone (n=55) or SOX + apatinib (n=57), according to whether oral apatinib was administered. Disease-free survival (DFS), overall survival (OS), and safety were compared between the two groups. Results: High VEGFR-2 mRNA expression was detected in 30.8% of stage III GC patients. All 112 patients had complete follow-up records, and the follow-up time was 59.3±24.2 months (range, 13-115 months). The 3-year DFS of the SOX group Conclusions: For stage III GC patients with high expression of VEGFR-2 mRNA, SOX + apatinib therapy could improve DFS and OS and had an acceptable safety. Thus, apatinib may potentially become another targeted drug in postoperative stage III GC patients. However, future large-scale randomized clinical trials are still needed for further verification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.